SAN DIEGO, CALIFORNIA, May 03, 2026
UCB has announced a definitive agreement to acquire Candid Therapeutics in a transaction valued at up to $2.2 billion, including $2 billion upfront and up to $200 million in milestone payments. The acquisition significantly strengthens UCB’s position in immunology and next-generation biologics, adding a portfolio of T-cell engager (TCE) therapies designed to treat autoimmune and inflammatory diseases. The deal reflects UCB’s strategic focus on inorganic growth and innovation, aiming to deliver transformative therapies for patients with severe immune-mediated conditions.
Strategic Acquisition Expands Immunology Pipeline
The acquisition of Candid Therapeutics provides UCB with access to a cutting-edge pipeline of T-cell engager antibodies, including its lead asset cizutamig, a bispecific antibody targeting BCMA on plasma cells and CD3 on T-cells. This mechanism enables targeted immune cell activation, resulting in the elimination of pathogenic B-cell populations that drive autoimmune diseases.
Cizutamig is currently being evaluated in multiple Phase 1 clinical studies across more than 10 autoimmune indications, highlighting its broad therapeutic potential. By integrating this platform, UCB enhances its ability to address complex immune-mediated diseases through precision biologics, moving beyond traditional therapies toward disease-modifying and potentially curative approaches.
T-Cell Engager Technology Drives Next-Generation Therapies
Advertisement
Candid’s proprietary T-cell engager (TCE) platform represents a novel therapeutic modality designed to achieve deep and targeted depletion of disease-causing immune cells, enabling what is described as an “immune reset”. Unlike conventional immunosuppressive treatments, TCEs leverage the body’s own immune system to selectively eliminate pathogenic cells while preserving overall immune function. Cizutamig has already been studied in over 100 patients across oncology and autoimmune settings, demonstrating promising clinical activity and manageable safety profiles.
Additionally, Candid is developing a pipeline of multi-specific TCE antibodies targeting different B-cell subsets, allowing for comprehensive disease control and improved durability of response. This approach aligns with the growing trend toward multi-target biologics and personalized immunotherapy, which are transforming the treatment landscape for chronic immune disorders.
Strengthening Biopharma Innovation and Global Strategy
The transaction builds on UCB’s broader strategy to expand its immunology leadership through strategic acquisitions, including recent investments in complementary platforms targeting B-cell biology and immune modulation.
From a GxP perspective, the continued development of cizutamig and related therapies will adhere to Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) standards, ensuring high-quality clinical data, regulatory compliance, and patient safety. Autoimmune diseases affect millions globally and often require long-term treatment with limited efficacy and significant side effects, underscoring the need for innovative and targeted therapeutic solutions.
By combining UCB’s global development and commercialization expertise with Candid’s innovative technology platform, the acquisition positions the company to accelerate the delivery of next-generation immunotherapies. This deal represents a significant milestone in the evolution of precision immunology, offering the potential to redefine treatment standards and improve quality of life for patients with severe autoimmune diseases, while reinforcing UCB’s role as a leader in biopharmaceutical innovation and strategic growth.
Source: UCB, Candid Therapeutics press release
